BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

EKF diagnostic GmbH HbA1c Analyzer Assessment Success Presented At World Diabetes Congress


12/3/2013 10:09:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Cardiff, UK – 3nd December 2013 – EKF Diagnostics, the global diagnostics business, announces the successful assessment of its Quo-Test and Quo-Lab point-of-care HbA1c analyzers within the College of Medicine, Swansea University. Dr Stephen Luzio, Associate Professor at the University, is giving a scientific poster presentation entitled ‘Assessment of two point-of-care analyzers for the determination of HbA1c’ at the World Diabetes Congress – International Diabetes Federation (IDF) 2013, Melbourne, Australia, 2nd to 6th December.

Glycated hemoglobin (HbA1c) is widely used as a means of monitoring diabetes control and has recently been recommended for use as a method of diabetes diagnosis. Measurement of HbA1c with point-of-care analyzers (POCT) has the advantage that samples can be determined on site, while a patient is still in the clinic. Dr Luzio and his team have successfully compared EKF’s Quo-Test and Quo-Lab POCT HbA1c analyzers with an established laboratory HPLC method (D10, Biorad).

Dr Luzio’s scientific poster concludes that, “Use of the Quo-Test and Quo-Lab HbA1c POCT analyzers, provides a rapid, accurate and reproducible method of determination of HbA1c, with results comparable to an established laboratory HPLC method. Both have the benefit of being able to generate results immediately in the clinical setting, providing greater convenience to the patient.”

Also at IDF 2013, EKF Diagnostics will showcase its Quo-Lab and Quo-Test HbA1c analyzers, as well as the Biosen C-Line glucose and lactate analyzer at Stand A15. Both Quo-Test and Quo-Lab use boronate fluorescence quenching technology to measure HbA1c from just 4 µL of capillary or venous blood and deliver results within 4 minutes. The Biosen C-Line analyzer is used to measure glucose and lactate precisely and quickly, from 25 seconds, in clinics, laboratories and sports medicine facilities around the world.

The aim of IDF is to advance diabetes care and prevention, and to establish a cure worldwide. IDF organizes the World Diabetes Congress on a biennial basis in differing global locations, to uniquely bring together healthcare professionals, researchers, policy makers, and people with diabetes, their carers and families. Dr Luzio is also Portfolio Development Manager at the Diabetes Research Network which aims to promote existing strengths and potential in diabetes research and diabetes care in Wales.

For more information on EKF Diagnostics, please visit www.ekfdiagnostics.com.

About EKF Diagnostics

www.ekfdiagnostics.com

EKF Diagnostics Holdings plc specializes in the development, production and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new Molecular division focuses on molecular and companion diagnostics.

Point-of-care diagnostics: EKF Diagnostics’ expertise covers the entire in vitro diagnostics chain, from fermentation and enzyme production, to liquid reagent manufacture, design and building of world-class diagnostic devices, and distribution of rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.

Companion Diagnostics: In March 2013 EKF set up a new division to focus on molecular and companion diagnostics - EKF Molecular Diagnostics develops technologies for cancer gene detection. Through its acquisition of UK-based 360 Genomics and by offering innovative products with the potential to change current DNA extraction and detection practices, EKF is addressing the fast growing companion diagnostics market.

EKF Diagnostics products are sold in more than 100 countries around the globe. EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES